SNIBE(300832) 诚通证券·2024-12-05 10:55Investment Rating - The report initiates coverage with a "Buy" rating for the company [1][2][164]. Core Insights - The company is a leading player in the chemical luminescence in vitro diagnostics sector in China, benefiting from both domestic and international growth drivers [1][14]. - High-margin reagents are the primary source of profit for the company, with the X8 series instruments contributing significantly to testing volume [1][2]. - The domestic market for in-hospital testing is increasingly concentrated in tertiary hospitals, which are expected to capture a larger share of the domestic replacement market [1][2][32]. Summary by Sections Company Overview - The company, established in 1995, specializes in the research, production, and sales of automated chemical luminescence immunoassay instruments and reagents, holding a market share of 5.2% in 2021 [1][14]. - As of H1 2024, the company has achieved a coverage rate of 60.2% in domestic tertiary hospitals and serves medical terminals in 155 countries and regions [1][14]. Market Dynamics - The in vitro diagnostics (IVD) industry in China is experiencing a shift towards tertiary hospitals, which are expected to account for approximately 70% of the in-hospital testing market by 2023 [1][24][32]. - The chemical luminescence market in China has a low domestic replacement rate of about 30%, indicating significant growth potential as domestic companies increase their market share [1][76]. Financial Projections - Revenue projections for the company are estimated at CNY 46.2 billion, CNY 55.3 billion, and CNY 66.0 billion for 2024E, 2025E, and 2026E respectively, with a compound annual growth rate (CAGR) of 19.5% for net profit [2][164]. - The company’s net profit is projected to reach CNY 19.2 billion, CNY 23.2 billion, and CNY 28.1 billion over the same period [2][164]. Competitive Position - The company has a strong competitive position in the high-end market, with the X8 and T8 series instruments expected to capture significant market share in domestic replacements [1][14][32]. - The introduction of the SATLARS T8 automated sample processing system is anticipated to enhance the company's competitiveness in tertiary hospitals [1][123]. Valuation - The company's current PE-TTM is 29.21, indicating a stable valuation level that is considered low, with potential for upward movement as the market stabilizes [2][166].